Bioventus (BVS) Free Cash Flow Growth (3y) (2023 - 2026)
Bioventus (BVS) Free Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 41.96% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 25.48% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 35.42% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 250.09% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 12.01% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 35.65% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 20.87% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 9.23% |
| 10 | Bioventus | 972.23 Mn | 942.77 Mn | 105.67 Mn | 26.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 26.25% |
| Mar 28, 2026 | 96.98% |
| Dec 31, 2025 | 52.20% |
| Sep 27, 2025 | 175.84% |
| Jun 28, 2025 | 149.07% |
| Mar 29, 2025 | 1.50% |
| Dec 31, 2024 | 64.17% |
| Sep 28, 2024 | 15.73% |
| Jun 29, 2024 | -3.16% |
| Mar 30, 2024 | 29.80% |
| Dec 31, 2023 | -27.71% |
| Sep 30, 2023 | -37.23% |
| Jul 1, 2023 | 18.21% |
| Apr 1, 2023 | -60.17% |